From Untouchable to Editable: How 21st-Century Gene Editing Breakthroughs Clash with Systemic Barriers
Flora Peyvandi, former President of ISTH, recently shared an encourgaing post on gene editing on X:
”Precision gene editing progresses, despite challenges: They may be the products of tomorrow, but today’s health systems do not easily support their price-tags and complex administration requirements.”
Read the full article here.
Genetic Disorders — The Untouchables, or Are They?
As precision gene-editing technologies—such as CRISPR, base editing, and prime editing—continue to advance, they hold transformative potential for treating genetic diseases once considered unmanageable.
From rare blood disorders to inherited blindness, these therapies represent a new frontier in medicine.
However, despite the scientific breakthroughs, real-world implementation remains a challenge.
High development costs, complex delivery methods, and the need for specialized infrastructure have created significant barriers for health systems worldwide.
Closing this gap will be essential for ensuring equitable access to the future of genomic medicine.
Learn more on new advancements in the field of medicine from Hemostasis Today.
-
Aug 11, 2026, 02:54Tareq Abadl: The Ultimate Guide to Clinically Significant Antibodies
-
Aug 10, 2026, 17:35Chokri Ben Lamine: Balancing Holistic Care and Precision in Hematology
-
Aug 10, 2026, 17:14Anna Stanizzi: Patient Blood Management as a New Model of Personalized Care
-
Aug 10, 2026, 17:12Odong Christopher: New Research on Ischemic Stroke Prediction in Uganda
-
Aug 10, 2026, 16:58Jeff Szer AM: Advancing the Management of Paroxysmal Nocturnal Hemoglobinuria
-
Aug 10, 2026, 16:51Suebsarn Ruksakulpiwat։ A New Milestone in the Development of the Stroke Risk Screening Scales
-
Aug 10, 2026, 16:09Preetie Shetty Akkunje: Making Stroke Rehabilitation Accessible in Low-Resource Settings
-
Aug 10, 2026, 15:50The Next Antithrombotic Frontier: GPVI Inhibitors Beyond Aspirin
-
Aug 10, 2026, 15:47Edward Lee Carter: 61% of Patients on Reduced-Dose Apixaban Did Not Meet Label Criteria